• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动态对比增强和扩散加权磁共振成像对兔肝肿瘤血管破坏治疗的无创评估

Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.

作者信息

Shao Haibo, Ni Yicheng, Zhang Jian, Chen Feng, Dai Xu, Fan Guoguang, Sun Ziping, Xu Ke

机构信息

Department of Radiology, the First Affiliated Hospital of China Medical University, Shenyang, China.

Section of Radiology, Department of Medical Diagnostic Science, University of Leuven, Leuven, Belgium.

出版信息

PLoS One. 2013 Dec 23;8(12):e82649. doi: 10.1371/journal.pone.0082649. eCollection 2013.

DOI:10.1371/journal.pone.0082649
PMID:24376560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3871575/
Abstract

Evaluation of vascular disrupting treatment (VDT) is generally based on tumor size and enhancement on conventional magnetic resonance imaging (MRI) which, unfortunately, may be limited in providing satisfactory information. The purpose of the study is to evaluate consecutive changes of 20 rabbit VX2 liver tumors after VDT by dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging (DWI) at a 3.0 T MR unit. Twenty four hours after intravenous injection of Combretastatin A-4-phosphate (CA4P) at 20 mg/kg, DCE-MRI derived Maximum Slope of Increase (MSI) and Positive Enhancement Integral (PEI) decreased sharply due to sudden shutting down of tumor feeding vessels. DWI derived Apparent Diffusion Coefficient (ADC) in tumor periphery decreased because of ischemic cell edema. On day 4, an increase of MSI was probably caused by the recovery of blood supply. A remarkable increase of ADC represented a large scale of necrosis among tumors. On day 8, the blood perfusion further decreased and the extent of necrosis further increased, reflected by lower MSI and PEI values and higher ADC value. On day 12, a second decrease of ADC was noticed because the re-growth of periphery tumor. The experimental data indicate that the therapeutic effects of VDT may be noninvasively monitored with DCE-MRI (reflecting tumor blood perfusion) and DWI (reflecting the changes of histology), which provide powerful measures for assessment of anticancer treatments.

摘要

血管破坏治疗(VDT)的评估通常基于传统磁共振成像(MRI)上的肿瘤大小和强化情况,然而遗憾的是,这在提供满意信息方面可能存在局限性。本研究的目的是在3.0 T磁共振设备上,通过动态对比增强磁共振成像(DCE-MRI)和扩散加权成像(DWI)评估20只兔VX2肝肿瘤在VDT后的连续变化。以20 mg/kg静脉注射磷酸羟基喜树碱(CA4P)24小时后,由于肿瘤供血血管突然关闭,DCE-MRI得出的最大上升斜率(MSI)和正性增强积分(PEI)急剧下降。肿瘤周边的DWI得出的表观扩散系数(ADC)因缺血性细胞水肿而降低。在第4天,MSI的增加可能是由于血供恢复所致。ADC的显著增加表明肿瘤内出现了大面积坏死。在第8天,血液灌注进一步下降,坏死范围进一步扩大,表现为较低的MSI和PEI值以及较高的ADC值。在第12天,由于周边肿瘤的再生长,ADC出现了第二次下降。实验数据表明,VDT的治疗效果可以通过DCE-MRI(反映肿瘤血液灌注)和DWI(反映组织学变化)进行无创监测,这为评估抗癌治疗提供了有力手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/fcb2b112e36f/pone.0082649.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/dbbd40a9abff/pone.0082649.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/6057e6acf846/pone.0082649.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/fcb2b112e36f/pone.0082649.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/dbbd40a9abff/pone.0082649.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/6057e6acf846/pone.0082649.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/3871575/fcb2b112e36f/pone.0082649.g003.jpg

相似文献

1
Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.动态对比增强和扩散加权磁共振成像对兔肝肿瘤血管破坏治疗的无创评估
PLoS One. 2013 Dec 23;8(12):e82649. doi: 10.1371/journal.pone.0082649. eCollection 2013.
2
Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.在兔VX2肝肿瘤模型中,联合动态对比增强磁共振成像和微血管密度评估经皮乙醇注射后血管生成情况。
Magn Reson Imaging. 2016 Feb;34(2):177-82. doi: 10.1016/j.mri.2015.10.013. Epub 2015 Oct 27.
3
Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.磷酸藤黄酸A4治疗啮齿动物肝肿瘤:使用多参数磁共振成像与微血管造影和组织学相关的无创治疗评估
Invest Radiol. 2009 Jan;44(1):44-53. doi: 10.1097/RLI.0b013e31818e5ace.
4
The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.首项关于血管破坏剂 CA4P 在具有全分化和血管性的原发性肝细胞癌中的治疗功效的研究:大鼠 MRI 微血管造影-组织病理学相关性。
Int J Cancer. 2018 Oct 1;143(7):1817-1828. doi: 10.1002/ijc.31567. Epub 2018 Jul 3.
5
Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.血管靶向剂在大鼠肿瘤模型中的作用:动态对比增强磁共振成像与扩散加权磁共振成像
Radiology. 2005 Nov;237(2):492-9. doi: 10.1148/radiol.2372041638. Epub 2005 Sep 28.
6
The diagnostic efficiency of the perfusion-related parameters in assessing the vascular disrupting agent (CA4P) response in a rabbit VX2 liver tumor model.评估血管破坏剂(CA4P)在兔 VX2 肝肿瘤模型中反应的灌注相关参数的诊断效率。
Acta Radiol. 2022 Sep;63(9):1147-1156. doi: 10.1177/02841851211032450. Epub 2021 Jul 19.
7
Diagnostic performance of diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) MRI for the differentiation of benign from malignant soft-tissue tumors.弥散加权(DWI)和动态对比增强(DCE)MRI 对良恶性软组织肿瘤的鉴别诊断性能。
J Magn Reson Imaging. 2019 Sep;50(3):798-809. doi: 10.1002/jmri.26607. Epub 2019 Jan 20.
8
Diffusion-weighted magnetic resonance imaging to evaluate microvascular density after transarterial embolization ablation in a rabbit VX2 liver tumor model.在兔VX2肝肿瘤模型中,采用磁共振扩散加权成像评估经动脉栓塞消融后的微血管密度。
Magn Reson Imaging. 2014 Oct;32(8):1052-7. doi: 10.1016/j.mri.2014.05.011. Epub 2014 Jun 24.
9
Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.比较两种临床相关剂量的血管破坏剂在伴有多参数磁共振成像生物标志物的啮齿类肝脏肿瘤中的作用。
Anticancer Drugs. 2012 Jan;23(1):12-21. doi: 10.1097/CAD.0b013e328349dd60.
10
Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors.体素内不相干运动扩散加权磁共振成像监测血管破坏剂 CKD-516 对兔 VX2 肝肿瘤治疗效果的研究。
Radiology. 2014 Aug;272(2):417-26. doi: 10.1148/radiol.14131165. Epub 2014 Apr 3.

引用本文的文献

1
Feasibility of rabbit auricular VX2 tumor model as an experimental model for intra-arterial embolization.兔耳VX2肿瘤模型作为动脉内栓塞实验模型的可行性
PLoS One. 2025 Jan 30;20(1):e0316282. doi: 10.1371/journal.pone.0316282. eCollection 2025.
2
Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics.兔VX2肝肿瘤模型:临床、生物学、组织学及肿瘤微环境特征综述
Front Oncol. 2022 May 10;12:871829. doi: 10.3389/fonc.2022.871829. eCollection 2022.
3
Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI.

本文引用的文献

1
Marine-derived angiogenesis inhibitors for cancer therapy.海洋来源的血管生成抑制剂用于癌症治疗。
Mar Drugs. 2013 Mar 15;11(3):903-33. doi: 10.3390/md11030903.
2
Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.影像学技术作为肾细胞癌的预测和预后生物标志物。
Ther Adv Med Oncol. 2013 Mar;5(2):119-31. doi: 10.1177/1758834012463624.
3
Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
使用动态对比增强磁共振成像监测CA4P对兔VX2肝肿瘤的治疗效果。
Diagn Interv Radiol. 2021 Sep;27(5):587-594. doi: 10.5152/dir.2021.20010.
4
Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.微管蛋白结合剂急性效应的非侵入性评估:肿瘤血管破坏成像综述
Molecules. 2021 Apr 27;26(9):2551. doi: 10.3390/molecules26092551.
5
Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.能量多普勒超声和超声造影能无创显示犬癌症患者接受抗血管生成治疗后的肿瘤血管反应。
Sci Rep. 2019 Jun 25;9(1):9262. doi: 10.1038/s41598-019-45682-2.
6
MRI assessment of hepatocellular carcinoma after locoregional therapy.局部区域治疗后肝细胞癌的磁共振成像评估
Insights Imaging. 2019 Jan 29;10(1):8. doi: 10.1186/s13244-019-0690-1.
7
Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.放射性碘标记 Hoechst 33258 用于早期预测血管破坏剂治疗肿瘤反应的临床前评价。
Contrast Media Mol Imaging. 2018 Feb 26;2018:5237950. doi: 10.1155/2018/5237950. eCollection 2018.
8
CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours.CT光谱成像用于监测VEGF受体激酶抑制剂AG-013736对兔VX2肝肿瘤的治疗效果。
Eur Radiol. 2017 Mar;27(3):918-926. doi: 10.1007/s00330-016-4458-4. Epub 2016 Jun 10.
9
Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy.放射性碘化金丝桃素诱导坏死靶向放疗改善大鼠原位肝移植肉瘤模型热消融的治疗效果
Oncotarget. 2016 Aug 9;7(32):51450-51461. doi: 10.18632/oncotarget.9848.
10
Hepatocellular carcinoma: IVIM diffusion quantification for prediction of tumor necrosis compared to enhancement ratios.肝细胞癌:与增强率相比,基于体素内不相干运动(IVIM)扩散定量法预测肿瘤坏死情况
Eur J Radiol Open. 2015 Dec 8;3:1-7. doi: 10.1016/j.ejro.2015.11.002. eCollection 2016.
顺次全身给予 combretastatin A4 磷酸盐和放射性碘标记贯叶连翘素可发挥协同靶向治疗作用,延长携带双焦点肿瘤异种移植物的 SCID 小鼠的存活时间。
Theranostics. 2013;3(2):127-37. doi: 10.7150/thno.5790. Epub 2013 Feb 13.
4
Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology.不同的血管破坏剂 combretastatin A4 磷酸盐反应:使用 MRI 生物标志物、微血管造影和组织病理学对大鼠肝和皮下肿瘤同种异体移植物的比较研究。
Transl Oncol. 2013 Feb;6(1):42-50. doi: 10.1593/tlo.12367. Epub 2013 Feb 1.
5
Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.小分子序贯双重靶向治疗策略(SMSDTTS):从临床前实验到可能的临床抗癌应用。
J Cancer. 2013;4(2):133-45. doi: 10.7150/jca.5635. Epub 2013 Jan 22.
6
Evolution of the ablation region after magnetic resonance-guided high-intensity focused ultrasound ablation in a Vx2 tumor model.磁共振引导高强度聚焦超声消融后在 Vx2 肿瘤模型中的消融区域演变。
Invest Radiol. 2013 Jun;48(6):381-6. doi: 10.1097/RLI.0b013e3182820257.
7
Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models.VEGF 阻断后肿瘤灌注的快速下降可预测临床前肿瘤模型中长期的肿瘤生长抑制。
Angiogenesis. 2013 Apr;16(2):429-41. doi: 10.1007/s10456-012-9328-3. Epub 2012 Dec 13.
8
Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers.设计作为微管靶向的新型血管破坏剂的 combretastatin A-4 类似物,特别关注其顺式受限异构体。
Curr Pharm Des. 2013;19(10):1923-55. doi: 10.2174/1381612811319100013.
9
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.甲状腺切除术联合福司氟尿苷(CA4P)方案似乎提示在间变性甲状腺癌患者的生存改善。
Surgery. 2012 Dec;152(6):1078-87. doi: 10.1016/j.surg.2012.08.036.
10
Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.康普瑞汀 A-4 磷酸盐通过基于 MRI 的血管大小成像评估,影响肿瘤血管体积和大小分布。
Clin Cancer Res. 2012 Dec 1;18(23):6469-77. doi: 10.1158/1078-0432.CCR-12-2014. Epub 2012 Oct 15.